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Mesenchymal stromal cells (MSC) from the amniotic membrane of human term
placenta (hAMSC), and the conditioned medium generated from their culture
(CM-hAMSC) offer significant tools for their use in regenerative medicine mainly due
to their immunomodulatory properties. Interestingly, hAMSC and their CM have been
successfully exploited in preclinical disease models of inflammatory and autoimmune
diseases where depletion or modulation of B cells have been indicated as an
effective treatment, such as inflammatory bowel disease, lung fibrosis, would healing,
collagen-induced arthritis, and multiple sclerosis. While the interactions between hAMSC
or CM-hAMSC and T lymphocytes, monocytes, dendritic cells, and macrophages has
been extensively explored, how they affect B lymphocytes remains unclear. Considering
that B cells are key players in the adaptive immune response and are a central component
of different diseases, in this study we investigated the in vitro properties of hAMSC and
CM-hAMSC on B cells. We provide evidence that both hAMSC and CM-hAMSC strongly
suppressed CpG-activated B-cell proliferation. Moreover, CM-hAMSC blocked B-cell
differentiation, with an increase of the proportion of mature B cells, and a reduction of
antibody secreting cell formation. We observed the strong inhibition of B cell terminal
differentiation into CD138+ plasma cells, as further shown by a significant decrease of
the expression of interferon regulatory factor 4 (IRF-4), PR/SET domain 1(PRDM1), and
X-box binding protein 1 (XBP-1) genes. Our results point out that the mechanism by
which CM-hAMSC impacts B cell proliferation and differentiation is mediated by secreted
factors, and prostanoids are partially involved in these actions. Factors contained in the
CM-hAMSC decreased the CpG-uptake sensors (CD205, CD14, and TLR9), suggesting
that B cell stimulation was affected early on. CM-hAMSC also decreased the expression
of interleukin-1 receptor-associated kinase (IRAK)-4, consequently inhibiting the entire
CpG-induced downstream signaling pathway. Overall, these findings add insight into the
mechanism of action of hAMSC and CM-hAMSC and are useful to better design their
potential therapeutic application in B-cell mediated diseases.
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INTRODUCTION
Mesenchymal stromal cells (MSC) from the amniotic membrane
of human term placenta (hAMSC), and the conditioned
medium generated from their culture (CM-hAMSC) possess the
ability to modulate inflammation (1). This intriguing property
offers significant advantages for their use in the treatment of
inflammatory and immunomediated diseases, and in the field
of regenerative medicine (2). As a matter of fact, hAMSC
and their CM have been successfully exploited in different
preclinical disease models where inflammation occurs, including
lung (3–6) and liver (7) fibrosis, would healing (8–10), collagen-
induced arthritis (11, 12), multiple sclerosis (11), inflammatory
bowel disease (11), colitis (11, 13), sepsis (11), traumatic brain
injury (14), and Huntington’s disease (15). We and others have
demonstrated that hAMSC andCM-hAMSC suppress the in vitro
proliferation, inflammatory cytokine production, and functions
of T lymphocytes (16, 17), monocytes (10), dendritic cells (18),
macrophages (10), and natural killer cells (19), and are able to
induce a phenotype and functional switch of monocytes toward
macrophages with anti-inflammatory pro-regenerative M2-like
features (10, 17), and also support the expansion of regulatory
T cells (16, 17). These in vitro immunomodulatory actions have
been confirmed in preclinical studies (4, 11, 13). However, studies
which address how hAMSC or their CM affect B-cell functions
are lacking.
Together with T cells, B cells are key players in the adaptive
immune response, they are potent antigen presenting cells that
can produce both pro- and anti-inflammatory cytokines, and
have the capacity to generate terminally differentiated antibody-
secreting plasma cells (20–22). Thus, B cells represent important
targets for the treatment of multiple autoimmune disorders (23),
for the induction of graft survival (24), or for the treatment
of skin and lung fibrosis (25, 26), and can act as powerful
modulators of tissue regeneration (27, 28). There is evidence of
the ability of MSC to interact with B cells, however controversial
effects have been described (29, 30). Indeed, several authors
have demonstrated that MSC from bone marrow (BM-MSC)
and adipose tissue (AT-MSC) (31, 32) strongly inhibit B-cell
proliferation (31, 33–36), but this antiproliferative capacity has
not been confirmed by others (37–39). In addition, although a
significant inhibition of plasma cell formation and decrease of
immunoglobulin production has been shown in some studies
(31–36), an increased differentiation into plasma cells with
increased Ig production has been observed in others (38, 39).
Currently, there are only a few studies with placenta-derived
MSC, which are referred to MSC isolated from umbilical cord
(38, 40) or Wharton’s jelly (41). Moreover, these studies were
limited to the investigation of only mouse B cells (40), or cell lines
(Burkitt’s lymphoma cell lines) (41), or only analyzed the effect of
placenta MSC on the proliferation of B lymphocytes (42).
Abbreviations: hAMSC, human amniotic mesenchymal stromal cells; CM-
hAMSC, conditioned medium obtained by hAMSC culture; CM-hAMSC/PG,
conditionedmediumwithout prostanoids, obtained by hAMSC culture in presence
of indomethacin.
Therefore, in this study we investigated the in vitro properties
of hAMSC and CM-hAMSC on B-cell proliferation and
differentiation. We analyzed the possible mechanism of action
by which CM-hAMSC acts on B cells by examining the signaling
pathways involved in B-cell activation and the genes responsible
for plasma cell generation. Finally, since we have previously
shown that prostanoids are partially responsible for the hAMSC-
induced inhibition of T-cell proliferation (43), we investigated
whether they could be involved in the effects observed on B cells.
MATERIALS AND METHODS
Ethics Statement
The collection of human peripheral blood mononuclear cells
(PBMC) for research purposes was approved by the Regional
Departments of Transfusion Medicine (Rif. 523, July 7, 2016).
PBMC were obtained from healthy adult donors (n = 10) and
provided by Center of Immune Transfusion of Spedali Civili of
Brescia, Italy. Human term placentas (n = 15), recovered from
healthy women after vaginal delivery or cesarean section at term,
were provided by the Department of Obstetrics and Gynecology
of Fondazione Poliambulanza-Istituto Ospedaliero of Brescia,
Italy. Samples were collected after obtaining informed written
consent according to the guidelines set by the Comitato Etico
Provinciale of Brescia, Italy number NP 2243 (19/01/2016).
Isolation of Human Amniotic Mesenchymal
Stromal Cells and Preparation of
Conditioned Medium
Placentas were processed immediately after collection and cells
were isolated and directly used. Specifically, human amniotic
mesenchymal stromal cells (hAMSC) were obtained from the
mesenchymal region of the amniotic membrane as previously
described (44). Conditioned medium was generated by culturing
hAMSC (CM-hAMSC) for 5 days in 24-well plates (Corning, NY,
USA) at a density of 5 × 105 cells/well in 0.5ml of Ultraculture
complete medium, composed of Ultraculture medium (Sigma-
Aldrich, St Louis, MO, USA), supplemented with 2mM L-
glutamine (Sigma-Aldrich), and 100 U/ml penicillin and 100
mg/ml streptomycin (both from Sigma-Aldrich) as described
(43). To obtain CM devoid of prostanoids (CM-hAMSC/PG),
hAMSC were cultured in Ultraculture complete medium
supplemented with 10µM indomethacin (Sigma-Aldrich), a
cyclooxygenase inhibitor (10). At the end of culture, CM-hAMSC
and CM-hAMSC/PG were collected, centrifuged at 300 x g,
filtered through a 0.8µm sterile filter (Sartorius Stedim, Florence,
Italy), and kept frozen at −80◦C until use. Each experiment was
performed by pooling together conditioned medium obtained
from 3 to 4 different hAMSC donors.
Isolation of PBMC and B Cells
PBMC were separated from sodium citrate whole blood through
density gradient centrifugation (Histopaque, Sigma-Aldrich),
were frozen in fetal bovine serum (FBS, Sigma-Aldrich) with
10% DMSO (Sigma-Aldrich) and stored in liquid nitrogen. B
cells were isolated from PBMC (n = 5) by negative selection
using Pan B cell isolation kit and MACS R© separation columns
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(Miltenyi Biotec, Bergisch Gladbach, Germany), according to the
manufacturer’s instructions. The purity of the B cell population
was confirmed with flow cytometry by CD19 expression which
resulted >85–90% of the total cells recovered.
Activation of B Cells and Co-culture With
hAMSC or CM-hAMSC
PBMC or enriched B cells were labeled with the intracellular
fluorescent dye, carboxyfluorescein diacetate succinimidyl ester
(CFSE, ThermoFisher) to monitor cell division. Briefly, 1 ×
106 cells/mL were resuspended in PBS-0.5% FBS and incubated
with 1µM CFSE for 4min at 37◦C. The cells were then washed
three times in cold RPMI complete medium, composed of RPMI
1,640 medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 1% penicillin and streptomycin, and 1% L-
glutamine (all from Sigma Aldrich, St. Louis, Missouri, USA),
and 2 × 105 PBMC or 1 × 105 B cells were subsequently
plated in 96 well-tissue culture plate in Ultraculture complete
medium (Sigma-Aldrich). B cell proliferation was induced by
stimulating cells for 6 days with 2.5µg/ml CpG-ODN 2006
(Aurogene Srl, Rome, Italy). Activated PBMC or B cells were
cultured in the presence of 100 µl of CM-hAMSC or in
contact with 1 × 105 hAMSC, that were plated the day before
in RPMI complete medium, left to adhere overnight, and γ-
irradiated at 30Gy to block their proliferation. The amount
of CM-hAMSC and hAMSC used in the experiments was
previously determined by culturing PBMC in the presence of
different amounts of CM-hAMSC (100, 50, 10 µl/well) or
different concentrations of hAMSC (1 × 105, 0.5 × 105, 0.1
× 105). The final volume of each well was 200 µl. In all
experiments activated PBMC or B cells cultured alone were used
as control.
Flow Cytometry Analysis of B Cell
Proliferation and Subsets
Flow cytometry analysis of B cells was performed after 6 days
of co-culture with hAMSC or CM-hAMSC, as described above.
Dead cells were excluded by eBioscienceTM Fixable Viability
Dye eFluorTM 780 (Thermo Fisher Scientific, Waltham, MA
USA) staining, according to the manufacturer’s instructions. B
cell subsets were identified by staining for 20min at 4◦C with
the appropriate combination of fluorochrome-conjugated anti-
human antibodies: CD19 BV421 (clone HIB19, used at final
concentration of 1:200) or CD19 BB700 (SJ25C1, 1:200), CD3
BV510 (UCHT1, 1:100), CD14 BV510 (M8P9, 1:200), CD38
PE (HB7, 1:150), CD27 PE-Cy7 (M-T271, 1:100), CD138 APC
(44F9,1:67), all from BD Biosciences except for CD138 that
was from Miltenyi. After washing in stain buffer, consisting of
0.02% sodium azide and 0.1% bovine serum albumin in PBS
(Sigma-Aldrich), the cells were acquired on FACSAria III (BD
Biosciences). B cell proliferation was inferred by analysis of CFSE
dilution, and calculated as percentage of CD19+ proliferating
cells. Raw data were analyzed using FCS express v5.0 (DeNovo
Software, Los Angeles, CA, USA).
Flow Cytometry Analysis of CpG Sensors
and CpG-Induced B-Cell Signaling
Transduction
2 × 105 PBMC were plated in 96 well-tissue culture plate in
Ultraculture complete medium (Sigma-Aldrich) and stimulated
with 2.5µg/ml CpG-ODN 2006 (Aurogene Srl). Activated PBMC
were cultured alone or in the presence of 100 µl of CM-
hAMSC in a final volume of 200 µl. After 2 days of culture,
the effect of CM-hAMSC on CpG sensors (CD205, CD14,
TLR9) expressed on B cells was assessed by staining the cells
for 20min at 4◦C with CD19 BV421 (HIB19, 1:200), CD3
BV510 (UCHT1, 1:100), CD14 A647 (MΦP9, 1:200), CD205
(DEC-205) BB700 (MMRI-7, 1:100), all from BD Biosciences.
After a washing step, the cells were fixed and permeabilized
with Cytofix/cytoperm solution (BD Biosciences) for 20min
at 4◦C, washed with 1 × BD perm/wash buffer solution
(BD Biosciences), and stained for 20min at 4◦C with specific
antibody against CD289 (TLR9) PE (eB72-1665, 1:20) and
CD14 PE (MΦP9, 1:50). Finally, the cells were washed and
acquired. To analyze CpG-induced signaling transduction, cells
were collected and 2 × 106 cells/ml stimulated with 2.5µg/ml
CpG-ODN 2006 (Aurogene Srl) for 1 h. In order to preserve
phosphorylation state, the cells were fixed immediately after the
stimulation period by adding 1.5% methanol-free formaldehyde
(ThermoFisher) for 10min at room temperature (RT). Then,
the cells were washed and stained for 25min at 4◦C with
CD19 BV421 (HIB19, 1:200), CD14 BV510 (MΦP9, 1:200),
CD3 FITC (UCHT1, 1:100), all from BD Biosciences. After a
permeabilization step in cold 90% methanol for 15min at 4◦C
in the dark, the cells were stained, protected from light, for
1h at RT with BD PhosflowTM (BD Biosciences) fluorescently
conjugated antibodies against: IRAK-4 PE (clone L29–525,
1:20), p38 MAPK pT180/pY182 Alexa Fluor R© 647 (36/p38
pT180/pY182, 1:20), NF-κB p65 (pS529) Alexa Fluor R© 647 (K10-
895.12.50, 1:40), JNK (pT183/pY185) Alexa Fluor R© 647 (N9-
66, 1:40), ERK1/2 (pT202/pY204) PerCP-CyTM5.5 (20A, 1:20),
PDPK1 (pS241) PE (J66-653.44.17, 1:20), Akt (pS473) PE-CF594
(M89-61, 1:40), Stat1 (pY701) PE (4a, 1:33), Stat5 (pY694) PE-
Cy7 [47/Stat5(pY694), 1:20]. Finally, the cells were washed and
acquired on FACSAria III (BD Biosciences) and FCS express v.
5.0 (DeNovo Software, Los Angeles, CA, USA) was used for data
analysis. All the washing steps were performed with stain buffer
unless stated otherwise.
Quantitative Real-Time PCR
2 × 105 PBMC were plated in 96 well-tissue culture plates
in Ultraculture (Lonza) complete medium and stimulated with
2.5µg/ml CpG-ODN 2006 (Aurogene Srl). Activated PBMC
were cultured alone or in the presence of 100 µl of CM-hAMSC
in a final volume of 200 µl. PBMC were collected at days 3,
4, and 5 after culture, and washed with PBS (Sigma-Aldrich).
Total RNA was extracted using EZ1 RNA cell Mini Kit protocol
(Qiagen, Frederick, MD, USA), in a BioRobot EZ1 Advanced XL
Workstation. The iScript Advanced cDNA Synthesis Kit for RT-
qPCR (Biorad) was used for cDNA synthesis, and quantitative
real-time PCR was performed using a Biorad instrument CFX96
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TABLE 1 | Primer sequences of genes analyzed by quantitative real-time PCR.





























(Biorad) with technical triplicates in 96-well plates. SsoAdvanced
Universal SYBR Green Supermix (Biorad) was used following
manufacturer’s instructions in a total volume of 20 µl. The
real-time PCR cycling program was as follows: 30 s at 95◦C,
40 cycles of 10 s at 95◦C, 20 s at 58◦C. Data were analyzed
with the GeneGlobe Data Analysis Center (Qiagen). Primer
sequences, listed in Table 1, were purchased from Sigma-Aldrich.
The expression level of each mRNA was normalized to the level
of the endogenous controls β-ACTIN.
Flow Cytometry Analysis of Transcription
Factors
PBMC were plated and stimulated with CpG-ODN 2006
(Aurogene Srl) alone or in the presence of 100 µl of CM-
hAMSC as described above. After 5 days of culture, cells
were collected and protein expression of the transcription
factors BCL6, PAX-5, IRF-4, and BLIMP-1 was analyzed by
flow cytometry. After exclusion of dead cells by eBioscienceTM
Fixable Viability Dye eFluorTM 780 (Thermo Fisher Scientific)
staining, cells were stained for 20min at 4◦C with CD19
BB700 (SJ25C1, 1:200), CD3 BV510 (UCHT1, 1:100), CD14
BV510 (MΦP9, 1:200), CD27 PE-Cy7 (M-T271, 1:100), all
from BD Biosciences. After washing in stain buffer, the
cells were fixed and permeabilized with Transcription Factor
Buffer Set (BD Biosciences) for 40min at 4◦C, according to
the manufacturer’s instructions. Then, cells were stained for
40min at 4◦C with specific antibody against BCL6 BV421
(K112-91, 1:30), PAX-5 PE (1H9, 1:100), IRF-4 PE (Q9–343,
1:100), BLIMP-1 Alexa Fluor R© 647 (6D3, 1:100). Finally, the
cells were washed with Transcription Factor Buffer Set (BD
Biosciences), acquired on a FACSAria III (BD Biosciences), and
analyzed using FCS express v5.0 (DeNovo Software, Los Angeles,
CA, USA).
Analysis of Cytokine and Chemokines
PBMC were plated and stimulated with CpG-ODN 2006
(Aurogene Srl) alone or in the presence of 100 µl of
CM-hAMSC as described above. After 6 days of culture,
FIGURE 1 | Peripheral blood mononuclear cells (PBMC) (A) or enriched B
cells (B) were labeled with carboxy-fluorescein diacetate, succinimidyl ester
(CFSE) fluorescence. PBMC or B cells were stimulated in vitro with CpG to
induce B-cell proliferation (white bar, control) and cultured in contact with 1 ×
105 hAMSC (dashed gray bar) or in presence of 100 µl of CM-hAMSC (gray
bar). Unstimulated PBMC or B cells (black bar) were used as controls. After 6
days of culture, B-cell proliferation was measured with flow cytometry by the
analysis of CFSE dilution, and calculated as percentage of CD19+ proliferating
cells. Floating bars (min to max) with line at median of proliferation from 7 (A)
and 5 (B) individual experiments is reported. ***p < 0.001 vs. PBMC+CpG.
the supernatant was collected and stored at −80 ◦C. The
amount of human interleukin (IL)-2, IL-5, IL-8, IL-10, IL-21,
interferon γ-induced protein (IP-10/CXCL10), monocyte
chemoattractant protein-1 (MCP-1/CCL2), granulocyte-colony
stimulating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), and macrophage inflammatory
proteins (MIP)-1α was determined by a multiplex bead-
based immunoassay (BD CBA Flex Set system from BD
Biosciences). Samples were processed according to the
manufacturer’s instructions, acquired on a FACSAria III
(BD Biosciences), and analyzed with the FCAP Array software
(BD Biosciences).
Statistical Analysis
One-way analysis of variance (ANOVA) was used to evaluate
significance, and the Holm-Sidak correction for multiple
comparison was applied for data presented in Figures 1, 2,
6, 7. Two-way ANOVA with Sidak correction was applied
for data presented in Figure 3. A paired t-test was used for
data presented in Figure 5. P<0.05 was considered to be
statistically significant. Statistical analyses were performed using
GraphPad Prism software 6 (GraphPad Software, La Jolla,
CA, USA).
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FIGURE 2 | PBMC were labeled with carboxy-fluorescein diacetate, succinimidyl ester (CFSE) fluorescence, stimulated in vitro with CpG and cultured in presence of
different concentrations of CM-hAMSC. Unstimulated PBMC were used as controls. After 6 days of culture, B-cell proliferation and B-cell subsets were measured with
flow cytometry. Representative results and gating strategy applied are shown (A). After removal of dead cells by eBioscienceTM Fixable Viability Dye eFluorTM 780
exclusion and morphological (FSC, forward scatter and SSC, side scatter) gates, B cells were identified as CD19+ (and CD3−CD14−) cells. Then, B-cell proliferation
was measured by the analysis of CFSE dilution, and calculated as percentage of CD19+ proliferating cells. Mature B cells, memory B cells, and antibody secreting
cells (ASC), were herein identified in the gate of CD19+ cells as CD27−, CD27+/low, and CD27hiCD38hi, respectively. Finally, in the gate of ASC
(CD19+CD27hiCD38hi), plasma cells (PC) were identified as CD138+ and plasmablast (PB) as CD138−. The percentage of positive cells in each gate is reported (A).
Floating bars (min to max) with line at median from at least 9 individual experiments is reported for the percentage of proliferating B cells (B), mature B cells
(CD19+CD27−) (C), memory B cells (CD19+CD27+/low) (D), ASC (CD19+CD27hiCD38hi) (E), and the proportion of plasmablasts (CD138−) and plasma cells
(CD138+) (F). *p < 0.05, ***p < 0.001 vs. PBMC+CpG.
RESULTS
Impact of hAMSC and CM-hAMSC on B
Cell Proliferation
CpG ODN-2006 (from now on referred to as CpG) is a
synthetic oligonucleotide that induces B cell proliferation and
differentiation (45, 46). As expected, we observed that PBMC
stimulated with CpG showed a high proliferation of CD19+
B-cells while those cultured in the absence of CpG did
not proliferate (Figure 1A). CpG-activated PBMC co-cultured
with hAMSC showed a significant reduction of CD19+ B-cell
proliferation (Figure 1A). To determine whether the inhibitory
effect of hAMSC on B cell proliferation was contact-dependent or
mediated by secreted factors, we used the conditioned medium
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FIGURE 3 | PBMC were stimulated in vitro with CpG in absence or presence of 100 µl CM-hAMSC. After 3, 4, and 5 days of culture, PBMC were collected, and
quantitative real-time PCR was performed for the analysis of B-cell CLL/lymphoma 6 (BCL6) (A), and interferon regulatory factor 4 (IRF-4), PR/SET domain 1
(PRDM1), X-box binding protein 1 (XBP-1), and syndecan 1 (SDC1/CD138) (B). The fold change in mRNA expression in PBMC+CpG and PBMC+CpG+CM-hAMSC
vs. unstimulated PBMC collected at day 3 is reported. Data are expressed as floating bars with line at median from at least 3 independent experiments, *p < 0.05, **p
< 0.01, ***p < 0.001 vs. PBMC+CpG. The protein expression of the transcription factors BCL6, paired box 5 (PAX-5), B lymphocyte induced maturation protein-1
(BLIMP-1), and IRF-4 was evaluated by flow cytometry. Representative results of 4 independent experiments are shown (C).
obtained from hAMSC culture (CM-hAMSC). As shown in
Figure 1A, CM-hAMSC alone was sufficient to suppress CD19+
B cell proliferation, implying that hAMSC do not require cell-
to-cell contact to carry out this particular function. Interestingly,
similar results were obtained with purified B-cells (Figure 1B),
indicating that inhibition of proliferation is exerted directly by
hAMSC and CM-hAMSC on B cells and is likely not mediated by
a third-party subset.
Impact of CM-hAMSC on B Cell
Sub-Populations
Having demonstrated that cell-to-cell contact is not necessary
for B cell inhibition, we performed subsequent experiments
with CM-hAMSC. First, different doses of CM-hAMSC
corresponding to 1/2 (100 µl), 1/4 (50 µl), and 1/20 (10 µl) of
the total volume of culture medium were evaluated. Inhibition
of proliferation by CM-hAMSC was dose-dependent, indeed
the capacity of CM-hAMSC to suppress B-cell proliferation
increased with the dose (Figure 2B). We next sought to
investigate the effect of CM-hAMSC on the principal B-cell
subsets: mature B cells, memory B cells, and antibody-secreting
cells (ASC), based on the different expression of CD27 and
CD38 on CD19+ B cells (47, 48) (Figure 2A). Unactivated
peripheral blood B cells mostly consisted of CD27− mature B
cells and CD27+/low memory B cells. In vitro CpG stimulation
induces both mature and memory B cells to proliferate and
to differentiate into ASC (45, 49). During proliferation and
differentiation, CD27 (as well as CD38) is highly up-regulated,
and increased expression of CD27 and CD38 were shown to
correlate with antibody secretion (45, 49). Therefore, after
CpG activation, CD27-positive cells represent heterogeneous
population of B cells, in which CD27hiCD38hi cells are those
with the higher frequency of ASC (50, 51). In contrast, non-
differentiated CD27+/low B cells were shown to preserve features
of non-secreting memory B cells (50, 51). Thus, mature B cells,
memory B cells, and ASC, were herein phenotypically identified
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in the CD19+ gate as CD27−, CD27+/low, and CD27hiCD38hi,
respectively (Figure 2A).
Compared to unactivated PBMC, CpG-stimulated PBMC
showed a strongly percentage of CD27hiCD38hi ASC (Figure 2E)
and a lower proportion of CD27− mature (Figure 2C) and
CD27+/low memory (Figure 2D) B cells. When CpG-
stimulation was performed in the presence of the highest
concentration of CM-hAMSC (100 µl), we observed an increase
of mature B cells (Figure 2C), and memory B cells (Figure 2D),
indicating the inhibition of B cell differentiation. In fact, in
the presence of the highest concentration of CM-hAMSC, the
differentiation of ASC was strongly and significantly suppressed,
while decreasing concentrations did not display any effect on
ASC formation (Figure 2E). There are currently two recognized
subsets of ASC: plasmablasts and plasma cells, which can be
discriminated based on their expression of the proteoglycan
CD138, a hallmark of terminally differentiated plasma cells
(48, 52). The few ASC found in the unactivated PBMC are
mainly composed of CD138− plasmablasts. On the other hand,
CD138+ plasma cells represent the majority of the CpG-activated
PBMC (Figure 2F). When activation of PBMC was performed
in the presence of CM-hAMSC, we observed a higher presence
of plasmablasts (and consequently a lower percentage of plasma
cells) compared to the control PBMC stimulated in absence
of CM-hAMSC. It is worth noting that, conversely to what we
observed with CD19+ cell proliferation and ASC formation, a
significant inhibition of plasma cells was also obtained at low
concentrations of CM-hAMSC (50 and 10µl) (Figure 2F). These
results indicate that CM-hAMSC contains different factors able
to strongly interfere not only with B-cell proliferation but also
with their differentiation.
Effects of CM-hAMSC on B-Cell Gene
Expression
The differentiation of B cells into terminally differentiated plasma
cells is under the control of several transcription factors. To better
understand the mechanism by which CM-hAMSC blocked B-cell
differentiation into plasma cells, we analyzed the gene expression
of transcription factors responsible for the transcription of B
cells, specifically B-cell CLL/lymphoma 6 (BCL6) and paired box
5 (PAX-5), and plasma cells, specifically interferon regulatory
factor 4 (IRF-4), PR/SET domain 1 (PRDM1), X-box binding
protein 1 (XBP-1), and syndecan 1 (SDC1/CD138). We observed
an increase of the B-cell gene BCL-6 in PBMC activated in
the presence of CM-hAMSC, that was statistically significant at
day 3 (Figure 3A), while there was no significant difference in
the PAX-5 expression (data not shown). Conversely, there was
a time-dependent increased expression of plasma cells genes
IRF-4, PRDM1, XBP-1, CD138 in PBMC activated with CpG,
all of which were strongly inhibited in presence of CM-AMSC
(Figure 3B). Further, to support these results, we analyzed the
protein expression of some transcription factors encoded by these
genes (Figure 3C) by flow cytometry. At day 5, in unactivated B
cells, the most highly expressed transcription factor was PAX-5.
After in vitroCpG-stimulation, B cells increased the expression of
BCL-6 and B lymphocyte inducedmaturation protein-1 (BLIMP-
1, the transcription factor encoded by PRDM1), and there was
a high production of IRF-4, consistent with the differentiation
of B cells into ASC. When CpG stimulation was performed in
presence of CM-hAMSC, we observed a slight increase of PAX-5,
and no change in BCL-6. On the contrary, CM-hAMSC strongly
inhibited the expression of IRF-4 and BLIMP-1, as observed at
the gene level. Altogether, these data confirmed the observation
that CM-hAMSC strongly blocked the terminally differentiation
of B cells into plasma cells.
Mechanism of Action of CM-hAMSC
To dissect the mechanism by which CM-hAMSC blocks B
cell proliferation and differentiation, we examined the signaling
pathways activated by CpG (outlined in Figure 4). Specifically,
we analyzed the expression of CD205, CD14, TLR9, IRAK4, NF-
κB, JNK1/2, p38 MAPK, ERK1/2, AKT, PDPK1, STAT1, and
STAT5. PBMC were activated with CpG and cultured in the
absence or presence of CM-hAMSC for 2 days. We then analyzed
the expression of CpG sensors on CD19+ B cells. We found
that the percentage of expression of CD205 was not affected
by the presence of CM-hAMSC (Figure 5A). However, CM-
hAMSC significantly decreased the cellular density expression
of CD205, evaluated as median fluorescence intensity (MFI) of
the receptor (CD205 MFI of PBMC+CpG= 766; CD205 MFI of
PBMC+CpG+CM-hAMSC = 467, n = 5; p < 0.05; Figure 5B).
Moreover, the intracellular expression of both TLR9 and CD14
was decreased in the presence of CM-hAMSC (Figure 5A).
Furthermore, we found that in the presence of CM-hAMSC the
expression of IRAK-4 was reduced, with a consequent reduced
phosphorylation in the transactivation domain of NF-κB p65
subunit, and a reduced phosphorylation of the all three MAPK
analyzed: JNK1/2, p38MAPK, and ERK1/2 (Figure 5C). Of note,
with the exception of IRAK-4, the other monoclonal antibodies
used in this assay recognized the phosphorylated, therefore the
activated form of the molecules. Again, we observed that CM-
hAMSC reduced the expression of the phopho-PDPK1 and -AKT
(Figure 5C), indicating that even this TLR-9 pathway is affected
by CM-hAMSC. Finally, we found that CM-hAMSC reduced the
expression of both phospho-Stat-1 and Stat-5 which play a central
role in transmitting cytokine signals (Figure 5C). Altogether,
these results demonstrate that CM-hAMSC is able to influence
early CpG-induced B cell stimulation by reducing the expression
of all the three principal CpG sensors (CD205, TLR9, and CD14),
as well as the expression of IRAK-4, consequently inhibiting the
entire downstream signaling pathway.
Effect of CM-hAMSC on Cytokine
Production
Human B cells, in addition to their well-established role in
adaptive immunity, may also regulate innate immunity through
the production of cytokines and chemokines. For this reason,
we investigated how CM-hAMSC could affect the production
of cytokines and chemokines released in the supernatants of
PBMC activated with CpG. We analyzed several cytokines and
chemokines reported to be produced by PBMC activated via TLR,
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FIGURE 4 | Outline of the signaling pathways activated by CpG. CD205 (DEC-205) is the main cell surface receptor for CpG and has a fundatmental role inCpG
uptake and delivery to the endosomal TLR9 (53, 54). In addition to CD205, TLR9 is the primary receptor involved in CpG-signaling pathway induction, along with its
co-receptor CD14 (55). TLR9 engagement in B cells is followed by the recruitment of the Myddosome complex, composed of MyD88, interleukin-1
receptor-associated kinase (IRAK)-4, and IRAK-1, where phosphorylation of IRAK1 and 4 triggers downstream signaling resulting in the activation of NF-κB signaling
pathways and mitogen-activated protein kinases (MAPK) (56, 57). An alternative TLR-9-dependent pathway that also controls both early B cell activation and
proliferation is represented by the phosphorylation of CD19 mediated by MyD88 (through interaction with PYK2/LYN complexes). CD19 can be regarded as one of the
main regulators of PI3K activity and inducer of PDPK1 and AKT (at S473) phosphorylation (58). Arrows indicate activating phosphorylation; dashed lines indicate
outcome of signaling; blue boxes indicate the CpG sensors analyzed; red boxes indicate the molecules involved in CpG signaling transduction analyzed.
such as IL-8, IP10/CXCL10, MCP-1, G-CSF, GM-CSF, and MIP-
1α (59), and cytokines important for plasma cell differentiation,
such as IL-5, IL-2, IL-10, IL-21 (45). CpG-stimulated PBMC did
not produce IL-2, IL-5, and IL-21, and we did not observed any
change in presence of CM-hAMSC (data not shown). Instead,
stimulated PBMC released the pro-inflammatory cytokines IL-
8 and IP10/CXCL10, the production of which was completely
blocked in presence of CM-hAMSC (Figure 6). Finally, CpG-
stimulated PBMC also secreted MCP-1, IL-10, and low amounts
of GM-CSF and MIP-1α, and the levels of these cytokines and
chemokines increased in presence of CM-hAMSC. However, the
variations observed could be very likely be simply ascribed to the
basal concentration of the cytokines present in the CM-hAMSC
(Figure 6).
Involvement of Prostanoids in B-Cell
Inhibition
Since we have previously shown that prostanoids are abundantly
represented in CM-hAMSC and are partially responsible for
the hAMSC-induced inhibition of T-cell proliferation (43), we
investigated whether they could be involved in the effects
observed on B cells. For this purpose, we produced CM-hAMSC
in presence of indomethacin, a cyclooxygenase inhibitor, to
specifically inhibit the production of prostanoids (PG), and we
tested this medium (CM-hAMSC/PG) on CpG-activated PBMC.
As expected, the control CM-hAMSC was able to block B-
cell proliferation, instead the effect of CM-hAMSC without
PG was significantly reduced (Figure 7A), suggesting a role of
prostanoids in the inhibition of B-cell proliferation. We next
tested the effect of CM-hAMSC/PG on B cell differentiation into
ASC and plasma cells. We observed that, compared to CM-
hAMSC, the block of ASC was also significantly reduced when
we applied the CM-hAMSC depleted of PG (Figure 7B), further
confirming the role of prostanoids affecting B cell function. In
contrast, when we investigated the composition of ASC, we
observed a significant (and comparable) inhibition of plasma
cells with both CM-hAMSC and CM-hAMSC/PG (Figure 7C).
Our results indicate that prostanoids strongly contribute to
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FIGURE 5 | PBMC were stimulated in vitro with CpG in absence or presence of 100 µl CM-hAMSC. After 2 days of culture, PBMC were collected and analyzed for
the expression of CpG sensors and molecules involved in CpG signaling transduction. The percentage of expression of CD205, TLR9, and CD14 on CD19+ cells (A)
and the median fluorescence intensity (MFI) of CD205-positive population / MFI CD205-negative population (B), was evaluated. IRAK4 and phospho NF-κB, JNK1/2,
p38 MAPK, ERK1/2, AKT, PDPK1, STAT1, and STAT5 levels were measured by phosphoflow. The normalized MFI ratio is presented (C), calculated as the ratio of the
median of phosphoflow-positive population/median of phosphoflow negative population for each condition (PBMC+CpG and PBMC+CpG+CM-hAMSC), and then
normalized against the control condition PBMC+CpG. Bars represent the mean ± SEM from at least 4 independent experiments, *p < 0.05, **p < 0.01 vs.
PBMC+CpG.
FIGURE 6 | PBMC were stimulated in vitro with CpG and cultured in presence of 100 µl of CM-hAMSC. After 6 days of culture, the supernatant was collected and
analyzed for the production of a panel of cytokines and chemokines. The amount of cytokines and chemokines present in the CM-hAMSC is represented on the right
part of each plot. Floating bars (min to max) with line at median from 3 independent experiments is reported. *p < 0.05, **p < 0.01, ***p < 0.001 vs. PBMC+CpG.
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FIGURE 7 | PBMC were labeled with CFSE fluorescence, stimulated in vitro with CpG and cultured in presence of 100 µl of CM-hAMSC or CM-hAMSC without PG
(CM-hAMSC/PG). Unstimulated PBMC were used as controls. After 6 days of culture, B-cell proliferation was measured by the analysis of CFSE dilution, and
calculated as percentage of CD19+ proliferating cells (A). In addition, the percentage of antibody secreting cells (ASC, CD19+CD27hiCD38hi) (B), and the proportion
of plasmablasts (CD138−) and plasma cells (CD138+) (C), were measured with flow cytometry. Floating bars (min to max) with line at median from at least 9 individual
experiments is reported. ***p < 0.001 vs. PBMC+CpG; §§§p < 0.001 vs. PBMC+CpG+CM-hAMSC; ns, not significant.
the CM-mediated modulation of CD19+ cell proliferation and
ASC formation, but they are not responsible for the terminal
inhibition of plasma cell differentiation.
DISCUSSION
The present study provides the first evidence that bothMSC from
the amniotic membrane (hAMSC) and the conditioned medium
generated from their culture (CM-hAMSC), strongly suppress B-
cell proliferation and differentiation, with an increase of mature
B cells and a reduction of ASC formation, thus abrogating
their terminal maturation into plasma cells. Indeed, we observed
the strong inhibition of the expression of the proteoglycan
CD138 and of IRF-4, PRDM1, and XBP-1 genes, all hallmarks
of terminally differentiated plasma cells. Our results point
out that the mechanism by which CM-hAMSC impact B cell
proliferation and differentiation is mediated by secreted factors
which affect the initial B cell stimulation, consequently inhibiting
the entire downstream signaling pathway. We also demonstrate
that prostanoids are partially involved in these actions.
In order to study the functions of the B-cell compartment, we
activated PBMC in vitro with the synthetic CpG oligonucleotide
(ODN) 2006, an extensively characterized CpG ODN class
B, among the most efficient inducers of B-cell activation,
proliferation and differentiation (45, 46). We observed that
not only hAMSC cultured in contact with PBMC, but also
their CM were able to inhibit CpG-induced B-cell proliferation.
Of note, hAMSC were not primed during CM preparation,
demonstrating that suppressive factors are constitutively secreted
by hAMSC without the need of activation, contrary to what
described for BM-MSC which CM was not able to inhibit B
cell proliferation (34). In contrast to hAMSC, some authors
reported that BM-MSC and AT-MSC need to be primed with
IFN-γ (32, 60) or in contact with T-cells (31, 35) to modulate B-
cell proliferation. The fact that hAMSC do not require priming
seems to be an intrinsic property of MSC derived from placenta,
possibly linked to the role of the placenta during fetal maternal
tolerance (61). B-cell differentiation has been linked to cell
division (62) and thus the ability of CM-hAMSC to inhibit
ASC could very likely be the consequence of the ability of CM-
hAMSC to suppress B-cell proliferation. As a matter of fact, CM-
hAMSC induced a dose-dependent inhibition of ASC generation
that mirrored the dose dependent inhibition of CD19+ B cell
proliferation. In addition to ASC suppression, we show the
capacity of CM-hAMSC to block the terminal differentiation
into CD138+ plasma cells. Our results are in line with those
obtained by others that show a reduction of Ig production
(31, 32, 34–36), and of CD138+ plasma cells (33, 36, 40), in
presence of BM-MSC or AT-MSC. Instead, in contrast with our
data, other authors have reported that BM-MSC and AT-MSC
increased differentiation into plasma cells with a consequent
increase of Ig production (38, 39). We also confirmed the
suppression of CD138+ plasma cell formation by the analysis
of several genes which encode transcription factors considered
to be master regulators of B cell terminal differentiation.
Specifically we analyzed PRDM1, the gene encoding for B
lymphocyte induced maturation protein-1 (BLIMP-1), described
to be uniquely required to drive plasmacytic differentiation and
maintenance of all Ig-secreting B cells (63). Blimp-1 is necessary
for the expression of J chain, X-box binding protein-1 (XBP-1),
another transcriptional activator that is required for plasma cell
development and function (64). In addition to PRDM1 and XBP-
1, we analyzed IRF-4 that binds and activates the transcription
of prdm1. While blimp-1-, xbp-1-, and irf-4-deficient mice
presented severe defects in Ab production (64–66), and therefore
are considered fundamental to drive plasma cell differentiation,
BCL-6 and PAX-5 are highly expressed in mature B cells and
are repressors of both prdm1 and XBP-1 (67, 68). Our data
showed that while the stimulation of PBMC with CpG induced
the expression of PRDM-1, XBP-1, and IRF-4, the levels of which
increased over time as previously reported (51), the presence of
CM-hAMSC increased the expression of BCL-6, and inhibited
PRDM-1, XBP-1, and IRF-4. Interestingly, XBP-1 was shown to
be upregulated in CD27hi cells (51), and its strong inhibition
induced by CM-hAMSC was congruent with the observed
suppression of CD27hiCD38hi ASC. Moreover, the suppression
of the transcription factors IRF-4 and BLIMP-1 was confirmed
by flow cytometry. Thus, the interference with PRDM-1, XBP-1,
and IRF-4 transcription could be a way by which CM-hAMSC
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targets plasma cell differentiation. Analyzing the signaling
pathway activated by CpG, we observed that the presence of
CM-hAMSC inhibited the downstream signaling triggered by
TLR9 engagement, specifically CM-hAMSC inhibited IRAK4
necessary for the activation of MAPK (JNK, p38 MAPK, ERK)
and NF-κB pathways (56, 57). The inhibition of NF-κB was
in line with the down-regulation of PRDM1 observed, since
NF-κB was reported to be a direct activator of Prdm1 after
TLR signals (69). In addition to the TLR9-MyD88-IRAK1/4
pathway, we analyzed the TLR9-PI3K-AKT pathway (58), and
we observed a significant decreased expression of phosphorylated
AKT after TLR9 stimulation in the presence of CM-hAMSC.
Overall, our data suggest that factors present in the CM-hAMSC
almost suppressed the entire pathway driven by CpG. Since it
is well-established that CpG acts upon ligation with its specific
ligand TLR9 in the endosomal compartment, we analyzed
TLR9 expression. Interestingly, in presence of CM-hAMSC, the
intracellular expression of TLR9 on B cells was significantly
reduced. In addition, CD14 was shown to act as a coreceptor for
endosomal TLR9 activation and promote the selective uptake of
CpG (55). Our results show that also the expression of CD14 was
reduced on B cells in CpG-activated PBMC in presence of CM-
hAMSC. Finally, we observed an inhibition of the surface density
expression of DEC-205/CD205, and this was of particular interest
due to its key role in the uptake of class B CpG ODN, including
the CpG ODN 2006 used in this study, able to shuttle CpG to
endolysosomes to encounter TLR9 (53), and thus suggesting a
reduction of CpG uptake. Signal transduction begins once TLR9
and its ligand are in the endolysosomal system, and although the
direct relationship between the expression of TLR9 in B cells and
the response mediated by CpG ODN remains elusive (70), for
the first time our data shows the downregulation of both CpG-
uptake sensors and TLR9 expression, and this could represent
an important mechanism by which CM-hAMSC inhibit B-cell
activation. Clearly, we cannot rule out that other mechanisms
might be involved, such as the impairment of proteolytic cleavage
of TLR9 in the endosome compartment, or the obstacle of
endosomal acidification, or the modulation of adaptor molecules
(e.g., TIRAP), all events of which have been described to be
necessary for proper TLR9 activation, regulation, and signal
transduction (46, 71–73).
Inhibiting factors from BM-MSC have been shown to
be contained in secreted extracellular vescicles (EV)-enriched
fractions, which were internalized by B lymphocytes and inhibit
CpG-induced B cell proliferation (74, 75) and IgM, IgG, and IgA
production (74). Contrarily, other authors have concluded that
inhibiting factors from AT-MSC are not preferentially located
in EV-enriched but rather in the EV-free (protein enriched)
fractions (76). Altogether these studies corroborate our findings
which highlighted a mechanism of action mediated by secreted
factors, however the specific factors responsible for B cell
immunomodulation are still unknown. Here, to gain an insight
into the factors involved in the suppression of B-cell proliferation
and differentiation induced by CM-hAMSC, we investigated
the role of prostanoids, since we have previously demonstrated
that they are highly found in the CM-hAMSC and are
partially responsible for the hAMSC-induced inhibition of T-cell
proliferation (43). While it was previously reported that MSC-
derived PGE2 can promote the proliferation and differentiation
of B-cells (38), our data demonstrate the involvement of
prostanoids in the inhibition of B cell proliferation and ASC
differentiation, in line with Su and colleagues, who described
the inhibition of IgE and IgG release from activated B-cells
in presence of TNF-α stimulated BM-MSC, and mediated
by a cyclooxygenase 2(COX2)/PGE2 signaling pathway (77).
Of note, CM-hAMSC without prostanoids was not able to
block B cell proliferation and ASC formation, indicating the
involvement of prostanoids in these effects. However, the block
of CD138+ plasma cell formation was maintained. Similarly, low
concentrations of CM-hAMSC were not able to inhibit either
B cell proliferation or ASC formation, but were sufficient to
maintain the block of plasma cell differentiation. These data
revealed that other factors other than prostanoids are responsible
for the block of the B cell terminal differentiation. CD138+
plasma-cell differentiation appears to be driven primarily by
the post-activation microenvironment rather than the initial
TLR-9–mediated activation event (45). Tabera and colleagues
reported that they did not observe a clear maturation of B
cells upon culture with CpG if plasmacytoid dendritic cells were
not present in the culture (36). In line with this, when we
stimulated purified B cells with CpG we observed the formation
of ASC (CD27hiCD38hi), but we did not observe the complete
differentiation into CD138+ plasma cells (data not shown).
Very likely, in our culture conditions, the other immune cells
present within PBMC could provide the molecules needed to
generate CD138+ plasma cells. As a consequence, we could
speculate that the factors present in CM-hAMSC responsible for
the block of the B cell terminal differentiation could also act
on the other immune cells involved in CD138 up-regulation.
Several cytokines and growth factors have been reported to be
essential to induce CD138 expression on plasma cells, including
IL-2, IL-5, IL-6, IL-10, IL-21, interferon-α, hyaluronate, and
human hepatocyte growth factor (45, 63). As previously reported
(59), we observed that CpG-stimulated PBMC did not produce
IL-2, IL-5, or IL-21, thus these cytokines very likely did not
contribute to CD138+ plasma cell formation in these culture
conditions. On the other hand, CpG-stimulated PBMC produced
the pro-inflammatory chemokines IL-8 and IP10/CXCL10, the
latter of which participates in plasma cell development (78),
and their release was completely blocked in the presence of
CM-hAMSC. Of note, IL-8 and IP10/CXCL10 inhibition is in
line with the suppression of p38, JNK, ERK1/2, AKT, NF-
κB, and STAT1 signaling pathway, involved in their induction
(79, 80). The modulation of B cell cytokine production, in
addition to the suppression of ASC, underlines the ability of
CM-hAMSC to modulate diverse activities of B cells. Indeed,
B cells play a well-established role in adaptive immunity by
the generation of terminally differentiated ASC (20–22), and
regulate innate immunity performing several immunological
functions, including antigen presentation, the induction of iNKT
expansion (81), and the production of multiple cytokines and
chemokines (20–22).
For these reasons, B cells are a central component of
many diseases, such as in autoimmune diseases including
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rheumatoid arthritis, systemic lupus erythematosus, or multiple
sclerosis. We and others have reported the improvement of
therapeutic outcome of collagen-induced arthritis (11, 12) and
multiple sclerosis (11) after hAMSC infusion. Whether these
improvement could be associated to a reduction of B cell
proliferation and ASC formation, as observed in vitro, need to
be investigated. Moreover, hAMSC and their CM have been
successfully applied in preclinical models of lung fibrosis (3–
6), where depletion of B cells represent important treatment
(25, 26). In addition to the suppression of B-cell proliferation,
we observed an increase of the proportion of mature naïve B
cells, which is of particular interest considering the recently
described role of mature naïve B cells in accelerating skin wound
closure (28).
In conclusion, this study clearly demonstrates the in vitro
activity of hAMSC and their CM on the modulation of B-
cell proliferation and terminal differentiation. Our results are
fundamental in order to understand the mechanism of action
of amniotic cells and their CM, and even though they need to
be confirmed by in vivo studies, they provide new insight into
the possible therapeutic applications and into the mechanism
of action through which they could support the restoration of
tissue integrity.
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